CASI Pharmaceuticals ( (CASI) ) has shared an update.
On April 3, 2025, CASI Pharmaceuticals announced an agreement to acquire all equity interests in Precision Autoimmune Therapeutics (PAT) from Wuxi Zhihe Daukang II Venture Capital Partnership. The transaction, valued at RMB28.4 million plus investment returns, will grant CASI sole global ownership of CID-103, a treatment for autoimmune diseases. This acquisition aligns with CASI’s strategy to expand its portfolio in autoimmune therapeutics and strengthen its market position.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company specializes in hematology oncology therapeutics, organ transplant rejection, autoimmune diseases, and other unmet medical needs, leveraging its China-based regulatory and commercial competencies and global drug development expertise.
YTD Price Performance: -29.19%
Average Trading Volume: 14,876
Technical Sentiment Signal: Strong Buy
Current Market Cap: $28.14M
Find detailed analytics on CASI stock on TipRanks’ Stock Analysis page.